Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab in Chinese patients with moderate-to-severe atopic dermatitis
CTR20262842Phase 3Active
- Sponsor
- Galderma
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nemolizumab in atopic dermatitis (AD), sponsored by Galderma. Started Oct 2026; status: active.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20262842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262842.